Physician profile
Molly Braddock
NPI 1881134765
$10,353.08
in general payments reported to CMS, 2019-2025
27 companies · $1,457 in 2025
The $1,457 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,178 · 2022: $1,666 · 2023: $2,817 · 2024: $3,234 · 2025: $1,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,922 · Education: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,922.18 |
| Education | $586.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,826.38 | 2021-2025 | |
| Janssen Biotech, INC. | $1,237.11 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $974.73 | 2021-2025 | Ilumya, Winlevi |
| Amgen INC. | $838.89 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $771.49 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $698.42 | 2022-2025 | Sotyktu |
| Pfizer INC. | $534.98 | 2021-2025 | |
| Leo Pharma INC. | $529.64 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $508.17 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $381.88 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $376.05 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $289.63 | 2022-2024 | Vtama |
| Genzyme Corporation | $245.83 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $201.76 | 2021-2025 | Libtayo, Dupixent |
| Sanofi-Aventis U.S. LLC | $157.13 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $151.97 | 2021-2025 | Arazlo, Cabtreo, Jublia |
| Almirall LLC | $140.02 | 2022-2024 | Klisyri, Seysara |
| Galderma Laboratories, L.P. | $97.69 | 2021-2025 | Aklief, Epsolay, Oracea |
| Biofrontera INC. | $94.97 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $71.17 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.83 | 2023-2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $53.00 | 2023-2024 | Ycanth |
| Organon LLC | $47.12 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $18.07 | 2021 | |
| Botanix Sb INC | $16.67 | 2025 | Sofdra |
| Mission Pharmacal Company | $15.97 | 2021 | |
| Epi Health, LLC | $14.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Braddock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.